Infectious Disease Genomics: Pathogen Evolution, Emergence, and Host Interaction

传染病基因组学：病原体进化、出现和宿主相互作用

• 批准号: 8688472
• 负责人: Bruce W. BIRREN
• 金额: $ 544.53万
• 依托单位: BROAD INSTITUTE, INC.
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-04-10 至 2019-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8688472
• 关键词: Address; Animal Model; Biological Models; Biology; Candida albicans; Categories; Cells; Clinical; Communicable Diseases; Communities; Complex; Dengue Virus; Developing Countries; Diagnosis; Disease Outbreaks; Economics; Enterobacteriaceae; Evolution; Exposure to; Fever; Fusarium; Genomics; Immune response; Infection; Infectious Diseases Research; Insect Vectors; Insecticides; Intervention; Knowledge; Laboratories; Lassa virus; Malaria; Measures; Methods; Monitor; Mycobacterium tuberculosis; National Institute of Allergy and Infectious Disease; Organism; Parasites; Pharmaceutical Preparations; Phenotype; Plasmodium falciparum; Population; Research; Research Personnel; Resources; Technology; Therapeutic; Training; Uropathogenic E. coli; Variant; Viral; Virulence; Virus; West Nile virus; Whole Organism; Work; analytical method; carbapenem resistance; drug sensitivity; experience; member; microbial community; mortality; mutant; pathogen; prevent; response; social; tool; transmission process; vector mosquito

DESCRIPTION (as provided by applicant): The staggering global toll taken by infectious diseases calls for vastly more effective monitoring, as well as new preventative and therapeutic measures. To address critical gaps in our knowledge about the basic biology of key pathogens and their interactions with their hosts and insect vectors, we will create a Genomic Center for Infectious Diseases (GCID). Our team combines an extensive track record of developing and applying groundbreaking laboratory and analytical methods with experience managing large and complex projects to produce resources for the infectious disease research community. We will use genomic methods to define the extent of variation among organisms, as well as among microbial communities. Our viral research will focus on the NIAID Category A priority pathogens Lassa and Dengue viruses, and the Category B priority pathogen West Nile virus, as well on surveillance for fever-causing viruses in tropical developing countries. Bacterial studies will focus on the Category C priority pathogens M. tuberculosis and Carbapenem-resistant Enterobacteriaceae, an emerging cause of nocosomial infections associated with high mortality, as well as the costly Uropathogenic E. coli. Fungal research will focus on major pathogens with significant clinical impact, C. neoformans and C. albicans, as well as strains causing recent fungal outbreaks, including C. gattii and Fusarium spp. We will also study both the malaria-causing parasite P. falciparum and its mosquito vector, A. gambiae. In studying these particular high-priority pathogens as model systems, we will produce, and train community members to use, new methods of wide utility. We will sequence natural isolates as well as laboratory-derived mutants, and associate sequence differences with phenotypes to help interpret the functional consequences of this variation with respect to virulence, transmission and drug sensitivity. Working at several levels, from populations to whole organisms, and animal models to single cells, we will reveal the long term (evolutionary) responses to pathogen and host interactions and exposure to drugs or insecticides as well as the immediate (transcriptional) responses of host and pathogens to infection. These responses define potential new opportunities for interventions to disrupt the cycle of infection and transmission. In bringing together outstanding investigators in infectious disease with cutting edge laboratory and analytical methods and experienced leaders in genomics, we will generate the information needed to create new tools to track, diagnose, treat and prevent infectious diseases. RELEVANCE: Infectious diseases continue to take a staggering social and economic toll on our global population. We will establish a center that will employ powerful, cutting edge technologies to probe the biology of a variety of dangerous pathogens and their interactions with their hosts. The information will directly inform new methods to monitor, prevent and treat infectious diseases.

描述（由申请人提供）：传染病造成的惊人的全球死亡人数要求更有效的监测以及新的预防和治疗措施。为了解决我们对关键病原体的基本生物学及其与宿主和昆虫载体相互作用的知识的关键差距，我们将创建传染病基因组中心（GCID）。我们的团队将开发和应用开创性实验室和分析方法的广泛记录与管理大型复杂项目的经验相结合，为传染病研究界提供资源。我们将使用基因组方法来定义生物体之间以及微生物群落之间的变异程度。我们的病毒研究将侧重于NIAID A类优先病原体拉沙病毒和登革热病毒，以及B类优先病原体西尼罗河病毒，以及监测热带发展中国家的发热病毒。细菌研究将集中在C类优先病原体M。结核病和耐碳青霉烯类肠杆菌科，与高死亡率相关的一种新的致病菌感染的原因，以及昂贵的泌尿系致病性E.杆菌真菌研究将集中在具有重大临床影响的主要病原体，C。新型隐球菌和白色念珠菌，以及最近引起真菌爆发的菌株，包括C。gattii和镰刀菌属（Fusarium spp.）我们还将研究引起疟疾的寄生虫恶性疟原虫及其蚊子载体，A。冈比亚。在研究这些特定的高优先级病原体作为模型系统时，我们将产生并培训社区成员使用具有广泛实用性的新方法。我们将对自然分离株和实验室衍生的突变体进行测序，并将序列差异与表型相关联，以帮助解释这种变异在毒力、传播和药物敏感性方面的功能后果。从种群到整个生物体，从动物模型到单细胞，我们将揭示病原体和宿主相互作用和暴露于药物或杀虫剂的长期（进化）反应，以及宿主和病原体对感染的即时（转录）反应。这些应对措施为采取干预措施打破感染和传播周期确定了潜在的新机会。在汇集了先进的实验室和分析方法和基因组学经验丰富的领导者在传染病的杰出研究人员，我们将产生所需的信息，创造新的工具来跟踪，诊断，治疗和预防传染病。 相关性：传染病继续给我们的全球人口带来惊人的社会和经济损失。我们将建立一个中心，采用强大的尖端技术来探测各种危险病原体的生物学及其与宿主的相互作用。这些信息将直接为监测、预防和治疗传染病的新方法提供信息。